Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1807 results
September 2016
-
Media ReleaseImportant new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patientsNew analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…
-
Media ReleaseNovartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patientsEXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary…
-
Media ReleaseNew Novartis data presented at ECTRIMS show benefit of Gilenya® on patient disability progression at 10 yearsACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya® (fingolimod) had significantly lower disability progression compared to those…
-
Media ReleaseNovartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraineDetailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine…
-
Three lessons I’ve learned as an industry postdoc
An immunologist shares tips from a team-based environment
-
Media ReleaseNovartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy CongressEmerging evidence from first 18 months of LPEP program demonstrates operational feasibility integrating single-dose rifampicin into routine control programs in 6 countries Retrospective…
-
Reaping cancer clues from the blood
NIBR investigator develops technology that uses tumor DNA in the blood for diagnostics
-
Media ReleaseNew Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisionsNijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions Point of care in office…
-
A cellular drama at the heart of a researcher’s family
Jennifer Allport-Anderson hunts for cardiac cures.
-
Media ReleaseAlcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experienceHeads-up design using high definition 3D screen engineered to improve surgeons posture and may reduce fatigue[1] Offers enhanced 3D visualization with high-definition resolution, image…
-
Media ReleaseNovartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groupsUltibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered…
-
Giving a small community a big voice
Read a patient’s perspective on living with a rare, life-threatening blood cancer called myelofibrosis and why it’s important to rally the community.
Pagination
- ‹ Previous page
- 1
- …
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- …
- 151
- › Next page